Equity research analysts covering TriSalus Life Sciences maintain a strongly favorable consensus rating, leaning toward a Strong Buy. Institutional forecasters highlight robust projected revenue growth driven by expanding adoption of the TriNav system, best-in-class gross margins in the mid-to-high 80s, and strategic catalysts aimed at achieving overall corporate cash flow positivity.